Charles River Laboratories International Inc. (CRL): Price and Financial Metrics

Charles River Laboratories International Inc. (CRL): $191.89

-5.57 (-2.82%)

POWR Rating

Component Grades














  • CRL scores best on the Growth dimension, with a Growth rank ahead of 85.66% of US stocks.
  • CRL's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • CRL's current lowest rank is in the Momentum metric (where it is better than 19.86% of US stocks).

CRL Stock Summary

  • CRL has a market capitalization of $9,880,485,277 -- more than approximately 84.1% of US stocks.
  • For CRL, its debt to operating expenses ratio is greater than that reported by 77.73% of US equities we're observing.
  • In terms of volatility of its share price, CRL is more volatile than just 21.79% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to CHARLES RIVER LABORATORIES INTERNATIONAL INC, a group of peers worth examining would be MSGE, ACHC, FLT, MLI, and PKG.
  • CRL's SEC filings can be seen here. And to visit CHARLES RIVER LABORATORIES INTERNATIONAL INC's official web site, go to

CRL Valuation Summary

  • CRL's EV/EBIT ratio is 18.9; this is 186.36% higher than that of the median Healthcare stock.
  • Over the past 243 months, CRL's price/sales ratio has gone up 0.4.

Below are key valuation metrics over time for CRL.

Stock Date P/S P/B P/E EV/EBIT
CRL 2023-03-24 2.5 3.3 20.3 18.9
CRL 2023-03-23 2.5 3.3 20.3 18.8
CRL 2023-03-22 2.5 3.4 20.6 19.0
CRL 2023-03-21 2.5 3.4 20.8 19.2
CRL 2023-03-20 2.5 3.3 20.2 18.8
CRL 2023-03-17 2.5 3.3 20.2 18.8

CRL Growth Metrics

    The year over year revenue growth rate now stands at 19.34%.
  • The 4 year cash and equivalents growth rate now stands at 183.17%.
  • The 3 year price growth rate now stands at 91.8%.
CRL's revenue has moved up $1,252,344,000 over the prior 34 months.

The table below shows CRL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 3,976.06 619.64 486.226
2022-09-30 3,781.267 614.141 436.394
2022-06-30 3,688.047 656.084 443.347
2022-03-31 3,629.523 693.2 422.474
2021-12-31 3,540.16 760.799 390.982
2021-09-30 3,426.1 669.92 396.595

CRL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRL has a Quality Grade of C, ranking ahead of 58.62% of graded US stocks.
  • CRL's asset turnover comes in at 0.564 -- ranking 280th of 561 Business Services stocks.
  • CRTO, OOMA, and SCWX are the stocks whose asset turnover ratios are most correlated with CRL.

The table below shows CRL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-26 0.564 0.379 0.141
2021-03-27 0.559 0.371 0.139
2020-12-26 0.553 0.367 0.135
2020-09-26 0.555 0.367 0.119
2020-06-27 0.558 0.361 0.101
2020-03-28 0.570 0.367 0.096

CRL Price Target

For more insight on analysts targets of CRL, see our CRL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $448.00 Average Broker Recommendation 1.35 (Strong Buy)

CRL Stock Price Chart Interactive Chart >

Price chart for CRL

CRL Price/Volume Stats

Current price $191.89 52-week high $308.15
Prev. close $197.46 52-week low $181.36
Day low $190.96 Volume 598,300
Day high $196.00 Avg. volume 582,381
50-day MA $227.99 Dividend yield N/A
200-day MA $220.15 Market Cap 9.78B

Charles River Laboratories International Inc. (CRL) Company Bio

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratorygene therapy and cell therapy services for the PharmaceuticalMedical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry (for example, contract research organization services) and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing. (Source:Wikipedia)

CRL Latest News Stream

Event/Time News Detail
Loading, please wait...

CRL Latest Social Stream

Loading social stream, please wait...

View Full CRL Social Stream

Latest CRL News From Around the Web

Below are the latest news stories about CHARLES RIVER LABORATORIES INTERNATIONAL INC that investors may wish to consider to help them evaluate CRL as an investment opportunity.

Why Is Charles River (CRL) Down 14.8% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 24, 2023

The total return for Charles River Laboratories International (NYSE:CRL) investors has risen faster than earnings growth over the last five years

It might be of some concern to shareholders to see the Charles River Laboratories International, Inc. ( NYSE:CRL...

Yahoo | March 16, 2023

Charles River's (CRL) New Cloud Platform Offers Real-Time Data

Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.

Yahoo | March 15, 2023

Charles River (CRL) Advances CDMO Portfolio With Latest Offer

Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.

Yahoo | March 14, 2023

Charles River Laboratories to Present at Barclays Global Healthcare Conference

WILMINGTON, Mass., March 13, 2023--Charles River Laboratories To Present At Barclays Global Healthcare Conference

Yahoo | March 13, 2023

Read More 'CRL' Stories Here

CRL Price Returns

1-mo -12.70%
3-mo -10.77%
6-mo 0.99%
1-year -32.12%
3-year 52.02%
5-year 79.77%
YTD -11.94%
2022 -42.17%
2021 50.80%
2020 63.56%
2019 34.97%
2018 3.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8044 seconds.